全文获取类型
收费全文 | 2680篇 |
免费 | 370篇 |
国内免费 | 2篇 |
专业分类
3052篇 |
出版年
2022年 | 27篇 |
2021年 | 37篇 |
2019年 | 23篇 |
2018年 | 27篇 |
2017年 | 32篇 |
2016年 | 50篇 |
2015年 | 87篇 |
2014年 | 90篇 |
2013年 | 113篇 |
2012年 | 127篇 |
2011年 | 129篇 |
2010年 | 84篇 |
2009年 | 81篇 |
2008年 | 117篇 |
2007年 | 109篇 |
2006年 | 92篇 |
2005年 | 103篇 |
2004年 | 103篇 |
2003年 | 109篇 |
2002年 | 101篇 |
2001年 | 80篇 |
2000年 | 96篇 |
1999年 | 71篇 |
1998年 | 47篇 |
1997年 | 51篇 |
1996年 | 40篇 |
1995年 | 37篇 |
1994年 | 22篇 |
1993年 | 39篇 |
1992年 | 55篇 |
1991年 | 46篇 |
1990年 | 42篇 |
1989年 | 55篇 |
1988年 | 30篇 |
1987年 | 26篇 |
1986年 | 37篇 |
1985年 | 37篇 |
1984年 | 51篇 |
1983年 | 27篇 |
1982年 | 31篇 |
1981年 | 26篇 |
1980年 | 32篇 |
1979年 | 28篇 |
1977年 | 36篇 |
1976年 | 23篇 |
1975年 | 23篇 |
1974年 | 24篇 |
1973年 | 27篇 |
1972年 | 26篇 |
1970年 | 31篇 |
排序方式: 共有3052条查询结果,搜索用时 15 毫秒
991.
992.
The inhibition of deoxyribonucleic acid nucleotidyltransferase by stilboestrol derivatives 总被引:4,自引:2,他引:2
下载免费PDF全文
![点击此处可从《The Biochemical journal》网站下载免费的PDF全文](/ch/ext_images/free.gif)
The inhibition by diethylstilboestrol of DNA nucleotidyltransferase isolated from calf thymus was studied. The inhibition exercised by diethylstilboestrol appears to obey competitive kinetics with respect to DNA primer. The activities of both replicative and terminal enzymes were affected to the same extent. There was no evidence of binding between DNA and diethylstilboestrol. A comparative study of the inhibitory effects of some stilboestrol derivatives is presented. The alkyl substitution in the alphaalpha'-positions seem to alter the inhibitory effect of these compounds: dimethylstilboestrol was more inhibitory than stilbene, and diethylstilboestrol was more inhibitory than dimethylstilboestrol. Hexoestrol, in which the alphaalpha'-ethylenic linkage is saturated, was the most effective inhibitor. 相似文献
993.
994.
Josie E. Parker Andrew G. S. Warrilow Hans J. Cools Bart A. Fraaije John A. Lucas Katarina Rigdova William J. Griffiths Diane E. Kelly Steven L. Kelly 《Applied and environmental microbiology》2013,79(5):1639-1645
Prothioconazole is a new triazolinthione fungicide used in agriculture. We have used Candida albicans CYP51 (CaCYP51) to investigate the in vitro activity of prothioconazole and to consider the use of such compounds in the medical arena. Treatment of C. albicans cells with prothioconazole, prothioconazole-desthio, and voriconazole resulted in CYP51 inhibition, as evidenced by the accumulation of 14α-methylated sterol substrates (lanosterol and eburicol) and the depletion of ergosterol. We then compared the inhibitor binding properties of prothioconazole, prothioconazole-desthio, and voriconazole with CaCYP51. We observed that prothioconazole-desthio and voriconazole bind noncompetitively to CaCYP51 in the expected manner of azole antifungals (with type II inhibitors binding to heme as the sixth ligand), while prothioconazole binds competitively and does not exhibit classic inhibitor binding spectra. Inhibition of CaCYP51 activity in a cell-free assay demonstrated that prothioconazole-desthio is active, whereas prothioconazole does not inhibit CYP51 activity. Extracts from C. albicans grown in the presence of prothioconazole were found to contain prothioconazole-desthio. We conclude that the antifungal action of prothioconazole can be attributed to prothioconazole-desthio. 相似文献
995.
996.
997.
998.
999.
Ajit Rayamajhi Sam Nightingale Nisha Keshary Bhatta Rupa Singh Elizabeth Ledger Krishna Prasad Bista Penny Lewthwaite Chandeshwar Mahaseth Lance Turtle Jaimie Sue Robinson Sareen Elizabeth Galbraith Malgorzata Wnek Barbara Wilmot Johnson Brian Faragher Michael John Griffiths Tom Solomon 《PloS one》2015,10(4)
Background
Japanese encephalitis (JE) virus (JEV) is a mosquito-borne flavivirus found across Asia that is closely related to West Nile virus. There is no known antiviral treatment for any flavivirus. Results from in vitro studies and animal models suggest intravenous immunoglobulin (IVIG) containing virus-specific neutralizing antibody may be effective in improving outcome in viral encephalitis. IVIG’s anti-inflammatory properties may also be beneficial.Methodology/Principal Findings
We performed a pilot feasibility randomized double-blind placebo-controlled trial of IVIG containing anti-JEV neutralizing antibody (ImmunoRel, 400mg/kg/day for 5 days) in children with suspected JE at two sites in Nepal; we also examined the effect on serum neutralizing antibody titre and cytokine profiles. 22 children were recruited, 13 of whom had confirmed JE; 11 received IVIG and 11 placebo, with no protocol violations. One child (IVIG group) died during treatment and two (placebo) subsequently following hospital discharge. Overall, there was no difference in outcome between treatment groups at discharge or follow up. Passive transfer of anti-JEV antibody was seen in JEV negative children. JEV positive children treated with IVIG had JEV-specific neutralizing antibody titres approximately 16 times higher than those treated with placebo (p=0.2), which was more than could be explained by passive transfer alone. IL-4 and IL-6 were higher in the IVIG group.Conclusions/Significance
A trial of IVIG for JE in Nepal is feasible. IVIG may augment the development of neutralizing antibodies in JEV positive patients. IVIG appears an appealing option for JE treatment that warrants further study.Trial Registration
ClinicalTrials.gov NCT01856205 相似文献1000.
Sanchita Das Mark S. Rundell Aashiq H. Mirza Maneesh R. Pingle Kristi Shigyo Aura R. Garrison Jason Paragas Scott K. Smith Victoria A. Olson Davise H. Larone Eric D. Spitzer Francis Barany Linnie M. Golightly 《PloS one》2015,10(9)
CDC designated category A infectious agents pose a major risk to national security and require special action for public health preparedness. They include viruses that cause viral hemorrhagic fever (VHF) syndrome as well as variola virus, the agent of smallpox. VHF is characterized by hemorrhage and fever with multi-organ failure leading to high morbidity and mortality. Smallpox, a prior scourge, has been eradicated for decades, making it a particularly serious threat if released nefariously in the essentially non-immune world population. Early detection of the causative agents, and the ability to distinguish them from other pathogens, is essential to contain outbreaks, implement proper control measures, and prevent morbidity and mortality. We have developed a multiplex detection assay that uses several species-specific PCR primers to generate amplicons from multiple pathogens; these are then targeted in a ligase detection reaction (LDR). The resultant fluorescently-labeled ligation products are detected on a universal array enabling simultaneous identification of the pathogens. The assay was evaluated on 32 different isolates associated with VHF (ebolavirus, marburgvirus, Crimean Congo hemorrhagic fever virus, Lassa fever virus, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia virus (the agent of smallpox and its vaccine strain, respectively). The assay was able to detect all viruses tested, including 8 sequences representative of different variola virus strains from the CDC repository. It does not cross react with other emerging zoonoses such as monkeypox virus or cowpox virus, or six flaviviruses tested (St. Louis encephalitis virus, Murray Valley encephalitis virus, Powassan virus, Tick-borne encephalitis virus, West Nile virus and Japanese encephalitis virus). 相似文献